´ëÇÑÁ¾¾ç³»°úÇÐȸ Liver Cancer Symposium : 2022-11-12±³À°ÀÏÀÚ : 2022-11-12
±³À°Àå¼Ò : ÀÎÅÍÄÜƼ³ÙÅ» ÄÚ¿¢½º
±³À°ÁÖÁ¦ :
Liver Cancer SymposiumÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : Â÷¹ÎÁÖ
¿¬¶ôó : 02-735-2857
À̸ÞÀÏ :
minju.cha@ksmo.or.kr ±³À°Á¾·ù : ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 09:00~09:25 Update of management for liver cirrhosis ÃÖ±¤Çö(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 09:25~09:45 Balancing efficacy vs toxicity: IO-IO vs IO-VEGF vs IO-TKI õÀç°æ(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 09:45~10:05 Managing Toxicities of Systemic Therapies to Maximize outcomes ±¸µ¿È¸(°ºÏ»ï¼ºº´¿ø)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 10:05~10:25 Current systemic therapy and ongoing clinical trials for BCLC stage B HCC ±èÇÑ»ó(¼¼ºê¶õ½º º´¿ø Á¾¾ç³»°ú)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 10:25~10:45 Locoregional vascular intervention for HCC - TARE/TACE ±è°æ¹Î(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 10:45~11:05 External radiotherapy for HCC À±»ó¹Î(¼¿ï¾Æ»ê ¹æÁ¾)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 11:05~11:25 Surgical approach for BCLC stage B HCC patients - Liver transplantation ÃÖ¿µ·Ï(¼¿ï´ëº´¿ø ¿Ü°ú)
ÈÞ½Ä 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 11:25~11:35 break time -(-)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 11:35~11:55 Who is the patient for systemic therapy? Çã¼®Àç(µ¿¾Æ´ëÇб³º´¿ø)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 11:55~12:15 Sequencing systemic therapies: can data guide us? ±èÀÏȯ(ÇØ¿î´ë¹éº´¿ø)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 12:15~12:35 Upcoming results of clinical trial for HCC therapy ¿À»óº¸(¾ç»êºÎ»ê´ëÇб³º´¿ø)
½Ä»ç 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 12:35~13:05 Luncheon(roche) ÀåÁ¤¼ø(Á߾Ӵ뺴¿ø)
ÈÞ½Ä 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 13:05~13:20 break time -(-)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 13:20~13:40 Image diagnosis for liver cancer ÀÌÇüÁø(¼¼ºê¶õ½º ¿µ»ó)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 13:40~14:05 Pathologic diagnosis for liver cancer ¹Ú¿µ³â(¼¼ºê¶õ½º º´¸®)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 14:05~14:25 Molecular subclassification of liver cancer À̼ºÈ¯(ºÐ´çÂ÷º´¿ø ¿Ü°ú)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 14:25~14:45 Change of first line chemotherapy À±Áö¼±(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 14:45~15:05 Later-line option and novel systemic treatment for cholangiocarcinoma ÀÌÃæ±Ù(¼¼ºê¶õ½º Á¾¾ç³»°ú)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 15:05~15:25 Perioperative chemotherapy and conversion surgery in cholangiocarcinoma ÀüÈ«Àç(ºÐ´çÂ÷º´¿ø Á¾¾ç³»°ú)
ÈÞ½Ä 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 15:25~15:35 break time -(-)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 15:35~15:50 Proposition ¹æ°æÇý(±¤¸í Á߾Ӵ뺴¿ø)
±³À°½Ã°£ 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 15:50~16:05 Opposition ±èÈ«½Ä(ÃæºÏ´ëº´¿ø)
Åä·Ð 11-12 ÀÎÅÍÄÜƼ³ÙÅ» ¼¿ïÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ 16:05~16:15 Discussion -(-)